Anavex Life Sciences, or Anavex has revealed promising new data from their ongoing research into Anavex 2-73
(blarcamesine), an investigational oral therapy targeting early Alzheimer’s
disease. The latest analysis from a Phase 2b/3 clinical trial indicates
significant cognitive and functional benefits for patients, marking a crucial
step forward in Alzheimer’s treatment. 

The study, involving 509 participants aged between 60 to 85, assessed the effects of
Anavex 2-73 over a 48-week period. Patients were administered one of two doses
of the drug or a placebo, with the primary focus on evaluating cognitive
function using the Alzheimer Disease Assessment Scale-Cognition (ADAS-Cog) and
overall functionality through the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living Scale (ADCS-ADL). 

Key findings demonstrated that those treated with Anavex 2-73 were 84% more likely to experience
meaningful cognitive improvement compared to the placebo group. Additionally,
the treatment showed a 45% slower cognitive decline and a 167% higher
likelihood of functional improvement over the placebo.

Blood analyses further supported these results, revealing significant reductions in the
amyloid-beta protein, a known marker linked to Alzheimer’s disease. MRI imaging
also indicated reduced brain volume loss among patients receiving Anavex 2-73,
underscoring its potential neuroprotective properties. 

Anavex Life Sciences is now preparing to engage with regulatory authorities in the U.S.,
Europe, and Asia-Pacific to discuss the approval pathway for Anavex 2-73.
“These findings bring hope for new treatment options that go beyond
amyloid targeting, potentially slowing disease progression in those with early
forms of Alzheimer’s,” said Marwan Noel Sabbagh, MD, of the Barrow Neurological Institute. 

Participants who completed the trial have the opportunity to join an open-label extension study,
ATTENTION-AD, to receive Anavex 2-73 for an additional two years. This next
phase aims to further validate the drug’s long-term efficacy and safety. 

Overall, the encouraging results from Anavex Life Sciences underscore the significant
advancements being made in Alzheimer’s research, offering new hope for patients
and their families. See related link for more information. 

More about Anavex Life Sciences on https://www.marketwatch.com/investing/stock/avxl